Novo Nordisk Faces Pressure After FY2026 Guidance Cut

Novo Nordisk A/S has experienced a significant market reaction following its announcement of lowered guidance for fiscal year 2026. The company reported a fourth-quarter revenue beat and an adjusted earnings per share (EPS) that exceeded consensus expectations, primarily driven by a remarkable 31% growth in its obesity-care segment. Despite these positive results, shares plummeted nearly 40% as investors reacted to the company’s disappointing forecast.

The decline in share value is attributed to several factors impacting Novo Nordisk’s profitability. The firm reported a compression in gross margins due to rising depreciation and amortization (D&A) costs as well as integration expenses. Additionally, increased research and development (R&D) and administrative costs contributed to a 290 basis point drop in the earnings before interest and taxes (EBIT) margin. This combination of factors has raised concerns about the company’s earnings momentum.

In its guidance for FY2026, Novo Nordisk anticipates a sales decline of 5% to 13%. The company cited various pressures, including pricing challenges in the U.S. market, impacts from the Most Favored Nation (MFN) rule, loss of exclusivity (LOE) effects, and shifts in product mix that are expected to outweigh planned volume growth. These developments have prompted analysts to reassess their positions on the stock.

Strategic Price Adjustments Ahead

To combat these challenges, Novo Nordisk plans to implement major price reductions for its leading products, Wegovy and Ozempic, starting in 2027. The strategy aims to drive significant volume expansion as the company integrates its recent acquisition of Catalent, which will enhance its fill-finish capacity on a global scale. This is seen as a critical move to bolster sales in an increasingly competitive environment.

Analysts note that despite the current challenges, Novo Nordisk appears to be trading at a substantial discount compared to its primary competitor, Eli Lilly. If the anticipated volume ramp-up occurs faster than expected and margins stabilize, there is potential for FY2027 EPS to exceed current consensus estimates, making the stock undervalued in the long term.

Victor Golmer, a prominent analyst in the pharmaceutical sector, has reiterated a Buy rating on Novo Nordisk’s stock, highlighting the firm’s strong fundamentals and growth prospects. He previously updated this rating in January, providing a preview for the company’s fourth-quarter performance, which has now contributed to a complex financial landscape for investors.

As Novo Nordisk navigates these challenges, it remains to be seen how effectively the company can execute its strategic plans and restore investor confidence. The situation underscores the importance of continuous monitoring of market dynamics and financial performance in the pharmaceutical industry.